Gallium Ga 68-edotreotide
Gallium Ga 68-edotreotide Uses, Dosage, Side Effects, Food Interaction and all others data.
Gallium Ga 68-edotreotide is an 8 amino acid peptide bound to the chelator 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA). Gallium Ga 68-edotreotide is indicated for localizing somatostatin receptor positive neuroendocrine tumors by positron emission tomography. Dotatate gallium Ga-68 is used for a similar indication. Dotatate gallium Ga-68 has lower tumor uptake but this data is highly variable between patients.
Gallium Ga 68-edotreotide was granted FDA approval on 21 August 2019.
Gallium Ga 68-edotreotide binds to somatostatin receptors where it emits beta particle radiation for detection by positron emission tomography. The duration of action is short as it has short radioactive and biological half lives. Patients should hydrate before and after the administration of this medication to encourage frequent urination and rapid clearance.
| Trade Name | Gallium Ga 68-edotreotide |
| Generic | Edotreotide gallium Ga-68 |
| Edotreotide gallium Ga-68 Other Names | Edotreotide Gallium Ga-68, Gallium (68Ga) edotreotide, Gallium edotreotide Ga-68, Gallium Ga 68-dotatoc, Gallium Ga 68-edotreotide, Gallium Ga-68 edotreotide |
| Type | |
| Formula | C65H89GaN14O18S2 |
| Weight | Average: 1486.55 Monoisotopic: 1485.520052927 |
| Protein binding | Data suggests edotreotide gallium-Ga 68 may bind to proteins in serum. The extent of serum protein binding and which proteins it binds to are not described in the literature. |
| Groups | Approved |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | September 19, 2023 at 7:00 am |
Uses
Gallium Ga 68-edotreotide is a radioactive diagnostic agent used in PET scans for somatostatin receptor positive neuroendocrine tumors in adult and pediatric patients.
Gallium Ga 68-edotreotide is a radioactive diagnostic compound used in positron emission tomography (PET) for diagnose somatostatin receptor positive neuroendocrine tumors in pediatrics and adults.
Gallium Ga 68-edotreotide is also used to associated treatment for these conditions: Neuroendocrine Tumors
How Gallium Ga 68-edotreotide works
Gallium Ga 68-edotreotide binds to somatostatin receptors, with higher affinity for somatostatin receptor type 2, where it emits beta particle radiation for detection by positron emission tomography (PET).
Toxicity
The LD50 of this medication is not readily available.
In the event of an overdose, give patients plenty of fluids and diuretics if necessary to encourage frequent urination. If possible, an estimation of radioactive dose should be performed.
Food Interaction
No interactions found.Volume of Distribution
Data regarding the volume of distribution of this medication is not readily available.
Elimination Route
Gallium Ga 68-edotreotide reaches 80% activity in tumors within 30 minutes, and reaches its highest activity in tumors 70±20min post injection. Edotreotide is mostly taken up into the spleen, followed by kidneys, liver, pituitary, thyroid, and adrenal gland. Accumulation in non-tumor tissue reaches a maximum within 40 minutes.
Half Life
Gallium Ga 68-edotreotide has a radioactive half life of 68 minutes. Gallium Ga 68-edotreotide has two half lives, 2.0±0.3min and 48±7min for its removal from blood.
Clearance
Data regarding the clearance of this medication is not readily available.
Elimination Route
16% of a Gallium Ga 68-edotreotide dose is eliminated in the urine within 2h. It is expected that Gallium Ga 68-edotreotide is exclusively eliminated in the urine. In animal studies, edotreotide Y-90 was >80% eliminated in the urine within 24h, with 95.6±3.4% being unmetabolized. 5
Innovators Monograph
You find simplified version here Gallium Ga 68-edotreotide
